Premium
Six autoantibodies as potential serum biomarkers of hepatocellular carcinoma: A prospective multicenter study
Author(s) -
Okada Rei,
Otsuka Yuichiro,
Wakabayashi Taiga,
Shinoda Masahiro,
Aoki Takeshi,
Murakami Masahiko,
Arizumi Shunichi,
Yamamoto Masakazu,
Aramaki Osamu,
Takayama Tadatoshi,
Wakiyama Shigeki,
Yanaga Katsuhiko,
Amikura Katsumi,
Kaneko Hironori,
Shimada Hideaki
Publication year - 2020
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.33165
Subject(s) - medicine , hepatocellular carcinoma , autoantibody , gastroenterology , prospective cohort study , antigen , antibody , carcinoma , immunology
Serum autoantibodies have been reported to react with tumor‐associated antigen (TAA) in various cancers. This multicenter study evaluated the diagnostic and prognostic value of six autoantibodies against a panel of six hepatocellular carcinoma (HCC)‐associated antigens, including Sui1, p62, RalA, p53, NY‐ESO‐1 and c‐myc. A total of 160 patients with HCC and 74 healthy controls were prospectively enrolled from six institutions. Serum antibody titers were determined by enzyme‐linked immunosorbent assays. The sensitivities were 19% for Sui1, 18% for p62, 17% for RalA, 11% for p53, 10% for NY‐ESO‐1 and 9% for c‐myc. Overall sensitivity of the TAA panel (56%) was higher than that of α‐fetoprotein (41%, P < .05). The combined sensitivity of the TAA panel and α‐fetoprotein was significantly higher than that of α‐fetoprotein alone ( P < .001). The difference in overall survival of TAA panel‐positive and panel‐negative patients was significant when the Stage I/II patients were combined ( P = .023). Overall survival was worse in NY‐ESO‐1 antibody‐positive than in NY‐ESO‐1 antibody‐negative patients ( P = .002). Multivariate analysis found that positivity for the TAA panel was independently associated with poor prognosis ( P = .030). This TAA panel may have diagnostic and prognostic value in the patients with HCC.